Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas.
Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas.
复制标题
外周 T 细胞淋巴瘤突变景观与生存结果的相关性
DOI：
10.1186/s40164-021-00200-x
复制
发表时间：
2021-02-05
影响因子：
10.9
通讯作者：
Zhu J
中科院分区：
文献类型：
--
作者：
Ye Y;Ding N;Mi L;Shi Y;Liu W;Song Y;Shu S;Zhu J
探讨外周T细胞淋巴瘤（PTCL）患者突变图谱与临床结局的相关性。
我们回顾性分析了2011年11月至2017年12月53例PTCL患者的临床病理及预后数据。对53例PTCL患者的组织进行了659个基因 panel的靶向二代测序。分析了突变图谱与临床结局的相关性。
TET2是突变频率最高的基因（64%），其次是RHOA（43%）、PCLO（23%）、DNMT3A（19%）、IDH2（17%）、PIEZO1（17%）和TP53（15%）。当将突变基因分类为功能组时，最常见的突变是那些涉及表观遗传/染色质修饰（75%）、T细胞活化（74%）以及DNA修复/TP53通路（64%）的突变。TET2/TP53突变与B症状阳性（P = 0.045）以及乳酸脱氢酶（LDH）水平升高（P = 0.011）显著相关。此外，TET2/TP53突变是PTCL患者生存的一个危险因素（风险比3.574，95%置信区间1.069 - 11.941，P = 0.039）。血管免疫母细胞性T细胞淋巴瘤（AITL）患者中JAK/STAT通路突变的发生导致无进展生存期更差（风险比2.366，95%置信区间0.9130 - 6.129，P = 0.0334）。
PTCL中存在异质性基因突变，其中一些对生存结局有负面影响。
ObjectiveTo explore the correlation of mutation landscape with clinical outcomes in patients with peripheral T-cell lymphoma (PTCL).MethodsWe retrospectively analyzed the clinicopathological and prognosis data of 53 patients with PTCL from November 2011 to December 2017. Targeted next-generation sequencing of a 659-gene panel was performed for tissues from 53 patients with PTCLs. The correlation of mutation landscape with clinical outcomes was analyzed.ResultsTET2was the most frequently mutated gene (64%), followed byRHOA(43%),PCLO(23%),DNMT3A(19%),IDH2(17%),PIEZO1(17%) andTP53(15%). When mutated genes were categorized into functional groups, the most common mutations were those involved in epigenetic/chromatin modification (75%), T-cell activation (74%), and the DNA repair/TP53 pathway (64%).TET2/TP53mutations were significantly associated with positive B symptoms (P= 0.045), and elevated lactate dehydrogenase (LDH) level (P= 0.011). Moreover,TET2/TP53mutation was a risk factor for PTCL patient survival (HR 3.574, 95% CI 1.069 − 11.941,P= 0.039). The occurrence of JAK/STAT pathway mutations in angioimmunoblastic T-cell lymphoma (AITL) patients conferred a worse progression-free survival (HR 2.366, 95% CI 0.9130–6.129,P= 0.0334).ConclusionsHeterogeneous gene mutations occur in PTCL, some of which have a negative impact on the survival outcome.
登录
查看更多内容
影响因子：
30.8
作者：
Palomero, Teresa;Couronne, Lucile;Khiabanian, Hossein;Kim, Mi-Yeon;Ambesi-Impiombato, Alberto;Perez-Garcia, Arianne;Carpenter, Zachary;Abate, Francesco;Allegretta, Maddalena;Haydu, J. Erika;Jiang, Xiaoyu;Lossos, Izidore S.;Nicolas, Concha;Balbin, Milagros;Bastard, Christian;Bhagat, Govind;Piris, Miguel A.;Campo, Elias;Bernard, Olivier A.;Rabadan, Raul;Ferrando, Adolfo A.
通讯作者：
Ferrando, Adolfo A.
影响因子：
50.3
作者：
Cortes JR;Ambesi-Impiombato A;Couronné L;Quinn SA;Kim CS;da Silva Almeida AC;West Z;Belver L;Martin MS;Scourzic L;Bhagat G;Bernard OA;Ferrando AA;Palomero T
通讯作者：
Palomero T
影响因子：
20.3
作者：
de Leval, Laurence;Rickman, David S.;Gaulard, Philippe
通讯作者：
Gaulard, Philippe
影响因子：
20.3
作者：
Castellar, Edgardo R. Parrilla;Jaffe, Elaine S.;Feldman, Andrew L.
通讯作者：
Feldman, Andrew L.
影响因子：
20.3
作者：
Schmitz, Norbert;Truemper, Lorenz;Pfreundschuh, Michael
通讯作者：
Pfreundschuh, Michael